Ex-Meta and DeepMind researchers raised $650m at a $4.65bn valuation for Recursive Superintelligence, a startup betting AI can automate its own research.

Incisive essays, intimate memoirs, and offbeat works of fiction contemplate the nature of motherhood and familial ...

With "Project Hail Mary" dominating the box office, author Andy Weir is steering fans toward Blake Crouch’s mind-bending ...

Project Hail Mary author Andy Weir keeps on recommending this sci-fi book everywhere he goes, and it's not hard to understand ...

The City and Its Uncertain Walls review explores Haruki Murakami’s latest novel on memory, identity and loss in a quiet, ...

Plus, pizza drama in the pizza capital, a podcast about your espresso machine, and Goop Kitchen arrives in New York ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...